A Prospective Registry of Pediatric Cellular Therapy Patients at Risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS).
Part of paid clinical trials in Rochester, Minnesota.
- Sponsor
- Duke University
- Study ID
- NCT05090345
- Status
- Recruiting
Conditions
- Hematopoietic Cell Transplantation
Eligibility Criteria
- Sex
- ALL
- Age
- 0 Years - 26 Years
- Healthy Volunteers
- Not accepted
Interventions
- Biorepository Trial — OTHERparticipating in this arm, peripheral blood specimen(s) will be obtained at 8 specified time-points.
Study Details
This is a prospective international multi-center registry and biorepository trial of children and adolescents/young adults (AYA) undergoing hematopoietic cell transplantation (HCT) to assess the impact of endotheliopathies in the HCT setting as a contributor of significant morbidity and mortality.
Key Dates
- Start date
- Nov 19, 2019
- Status verified
- May 2026
- Primary completion
- Feb 5, 2027
- Completion
- Feb 5, 2028
Study Design
- Enrollment
- 500 participants (estimated)
Arms
- Arm: Biorepository trial of children and adolescents/young adults (AYA)undergoing hematopoietic cell transplantation (HCT) to assess the impact of endotheliopathies in the HCT setting as a contributor of significant morbidity and mortality.
Primary Outcome Measure
Proportion of pediatric patients undergoing hematopoietic cell transplant (HCT) who develop endotheliopathies (SOS, TMA, DAH and IPS) and/or MODS within 100 days of such therapies. [ Time Frame: through study completion, an average of 1 year ]
Central Contacts
- LaTarsha Spencer(919) 613-1895
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic | Rochester | Minnesota | 55902 | Mira Kohorst |
| Duke University | Durham | North Carolina | 27705 | |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Dristhi Ragoonanan |
Find similar trials in Rochester, MN
Related Studies
- Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant RecipientsRecruiting · University of Michigan Rogel Cancer Center · Stanford, California
- CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and LymphomaPHASE1 · Recruiting · St. Jude Children's Research Hospital · Memphis, Tennessee